Amatem Forte is a combination antimalarial medication containing 80mg of Artemether and 480mg of Lumefantrine used to treat acute uncomplicated Plasmodium falciparum malaria in adults and children weighing 35kg or more.
Artemether and Lumefantrine target the malaria parasite's food vacuole, interfering with heme conversion. Lumefantrine disrupts heme polymerization, while Artemether creates reactive metabolites that interact with heme iron. They also inhibit nucleic acid and protein synthesis within the parasite.
Six tablets over three days, taken orally with food: Day 1: one tablet at 0 and 8 hours; Day 2: one tablet at 24 and 36 hours; Day 3: one tablet at 48 and 60 hours.
Yes. Hypersensitivity to ingredients, severe malaria, use of CYP2D6 metabolized drugs, family history of sudden death or long QTc interval, use of QTc prolonging drugs, history of cardiac arrhythmias, bradycardia, or congestive heart failure with reduced ejection fraction.
Common: decreased appetite, sleep disorders, headache, dizziness, cough, vomiting, abdominal pain, nausea, and diarrhea. Less common side effects are also possible.
Do not take with QTc prolonging drugs or CYP2D6 metabolized drugs. Not recommended with other antimalarials unless necessary. Caution with CYP3A4 inhibitors.
Not recommended during the first trimester unless life-threatening. Second and third trimesters only if benefit outweighs risk. Breastfeeding should be avoided during treatment and for one week after.
Contact your doctor or pharmacist immediately.
Dry place below 30°C (86°F), protected from light, and out of reach of children.
Artemether is rapidly metabolized by the liver (CYP3A4/5) to dihydroartemisinin. Both have a short half-life (≈2 hours). Lumefantrine is metabolized more slowly (CYP3A4) with a longer half-life (2-6 days). Excretion is primarily through feces.